Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy

Cancer Research

Volumn 59, Issue 10, 1999, Pages 2363-2369

  Schlemmer, Heinz Peter ^a,b   Becker, Markus ^a   Bachert, Peter ^a   Dietz, Andreas ^a   Rudat, Volker ^a   Vanselow, Bernhard ^a   Wollensack, Petra ^a   Zuna, Iwan ^a   Knopp, Michael V ^a   Weidauer, Hagen ^a   Wannenmacher, Michael ^a   Van Kaick, Gerhard ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FLUORO BETA ALANINE; CARBOPLATIN; DIHYDROFLUOROURACIL; FLUOROURACIL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DETOXIFICATION; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG UPTAKE; FEMALE; HEAD CANCER; HUMAN; MALE; NECK CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA-ALANINE; BIOTRANSFORMATION; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUORINE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; ISOTOPES; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED;

EID: 0033563129     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. O'Connell, M. J., Martenson, J. A., Wieand, H. S., Krook, J. E., Macdonald, J. S., Haller, D. G., Mayer, R. J., Gunderson, L. L., and Rich, T. A. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N. Engl. J. Med., 331: 502-507, 1994.
2. UKCCCR Anal Cancer Trial Working Party. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet, 348: 1049-1054, 1996.
3. Chakravarthy, A., and Abrams, R. A. Radiation therapy and 5-fluorouracil in pancreatic cancer. Semin. Radiat. Oncol., 7: 291-299, 1997.
4. Herskovic, A., Martz, K., Al-Sarraf, M., Leichman, L., Brindle, J., Vaitkevicius, V., Cooper, J., Byhardt, R., Davis, L., and Emami, B. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N. Engl. J. Med., 326: 1593-1598, 1992.
5. Fu, K. K. Radiation therapy with 5-fluorouracil in head and neck cancer. Semin. Radiat. Oncol., 7: 274-282, 1997.
6. Lawrence, T. S., Tepper, J. E., and Blackstock, A. W. Fluoropyrimidine-radiation interactions in cells and tumors. Semin. Radiat. Oncol., 7: 260-266, 1997.
7. Rich, T. A. Irradiation plus 5-fluorouracil: cellular mechanisms of action and treatment schedules. Semin. Radiat. Oncol., 7: 267-273, 1997.
8. Pu, A. T., Robertson, J. M., and Lawrence, T. S. Current status of radiation sensitization by fluoropyrimidines. Oncology (Huntingt.), 9: 707-714, 1995.
9. 19F nuclear magnetic resonance spectroscopy. Int. J. Radiat. Oncol. Biol. Phys., 36: 641-648, 1996.
10. 19F-NMR. Br. J. Cancer, 50: 113-117 1984.
11. Wolf, W., Albright, M. J., Silver, M. S., Weber, H., Reichardt, U., and Sauer, R. Fluorine-19 NMR spectroscopic studies of the metabolism of 5-fluorouracil in the liver of patients undergoing chemotherapy. Magn. Reson. Imaging, 5: 165-169, 1987.
12. Bachert, P. Pharmacokinetics using fluorine NMR in vivo. Progr. NMR Spectrosc., 33: 1-56, 1998.
13. 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study. Ann. Oncol., 4: 597-602, 1993.
14. Presant, C. A., Wolf, W., Waluch, V., Wiseman, C., Kennedy, P., Blayney, D., and Brechner, R. R. Association of intratumoral pharmacokinetics of fluorouracil with clinical response. Lancet, 343: 1184-1187, 1994.
15. 19F NMR study during 5-FU chemotherapy in patients with metastases of colorectal adenocarcinoma. Magn. Reson. Imaging, 12: 497-511, 1994.
16. International Union Against Cancer (UICC). Head and neck tumours. In: L. H. Sobin and Ch. Wittekind (eds.), TNM classification of malignant tumours, pp. 25-37. New York: Wiley-Liss, 1997.
17. Pinedo, H. M., and Peters, G. F. J. Fluorouracil: biochemistry and pharmacology. J. Clin. Oncol., 6: 1653-1664, 1988.
18. Byfield, J. E. 5-Fluorouracil radiation sensitization - a brief review. Invest. New Drugs, 7: 111-116, 1989.
19. 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment. Cancer Res., 48: 1680-1688, 1988.
20. Kish, J. A., Ensley J. F., Jacobs, J., Weaver, A., Cummings, G., and Al-Sarraf, M. A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP+5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer (Phila.), 56: 2740-2744, 1985.
21. 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. Proc. Natl. Acad. Sci. USA, 87: 492-496, 1990.
22. Semmler, W., Bachert-Baumann, P., Gückel, F., Ermark, F., Schlag, P., Lorenz, W. J., and van Kaick, G. Real-time follow-up of 5-fluorouracil metabolism in the liver of tumor patients by means of F-19 MR spectroscopy. Radiology, 174: 141-145, 1990.
23. Spoelstra, E. C., Pinedo, H. M., Dekker, H., Godefridus, J. P., and Lankelma, J. Measurement of in vitro cellular pharmacokinetics of 5-fluorouracil in human and rat cancer cell lines and rat hepatocytes using a flow-through system. Cancer Chemother. Pharmacol., 27: 320-325, 1991.
24. 19F MRS studies of fluoropyrimidine chemotherapy. A review. NMR Biomed., 2: 133-141, 1989.
25. Diasio, R. B., Schuetz, J. D., Wallace, H. J., and Sommadossi, J. P. Dihydrofluorouracil, a fluorouracil catabolite with antitumor activity in murine and human cells. Cancer Res., 45: 4900-4903, 1985.
26. Malet-Martino, M. C., Martino, R., Lopez, A., Béteille, J.-P., Bon, M., Bernadou, J., and Armand, J. P. New approach to metabolism of 5′-deoxy-5-fluorouridine in humans with fluorine-19 NMR. Cancer Chemother. Pharmacol., 13: 31-35, 1984.
27. Rowland, I. J., Maxwell, R. J., Baluch, S., Ojugo, A. S. E., Griffiths, J. R., and Leach, M. O. Differential distribution of 5-fluorouracil and α-fluoro-β-alanine in both rat liver and tumour. Proc. Soc. Magn. Reson. Med. (SMRM) 244, 1993.
28. Tozer, G. M., Bhujwalla, Z. M., Griffiths, J. R., and Maxwell, R. J. Phosphorus-31 magnetic resonance spectroscopy and blood perfusion of the RIF-1 tumor following X-irradiation. Int. J. Radiat. Oncol. Biol. Phys., 16: 155-164, 1989.
29. Li, S. J., Wehrle, J. P., Glickson, J. D., Kumar, N., and Braunschweiger, P. G. Tumor bioenergetics and blood flow in RIF-1 murine tumors treated with 5-fluorouracil. Magn. Reson. Med., 22: 47-56, 1991.
30. 195Pt NMR. J. Magn. Reson., 133: 115-122, 1998.
31. He, Q., Bhujwalla, Z. M., Maxwell, R. J., Griffiths, J. R., and Glickson, J. D. Proton NMR observation of the antineoplastic agent iproplatin in vivo by selective multiple quantum coherence transfer (Sel-MQC). Magn. Reson. Med., 33: 414-416, 1995.
32. 13N]cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors. J. Nucl. Med., 28: 1844-1852, 1987.